Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

NCT00112294 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

755

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small-Cell Lung Carcinoma

Interventions

DRUG: Paclitaxel (Taxane)
DRUG: Docetaxel (Taxane)
DRUG: Carboplatin
DRUG: Cetuximab

Sponsor

Eli Lilly and Company